Why carry out this study?

In Japan, several sodium glucose co-transporter 2 (SGLT2) inhibitors have been used for type 1 diabetes mellitus; however, there are no clinical reports regarding patient satisfaction related to SGLT2 inhibitor use.

What did the study ask?

Does the administration of a SGLT2 inhibitor in type 1 diabetes mellitus improve patient satisfaction?

What was learned from the study?

SGLT2 inhibitors concurrently improved clinical treatment satisfaction and glycemic variability in patients with type 1 diabetes mellitus.

With careful use, SGLT2 inhibitors do not induce any severe side effects.